Integrated Filing — IndAS



General information about company

Scrip Code 543271
NSE Symbol JUBLINGREA
MSEI Symbol NOTLISTED
ISIN INE0BY001018
Name of company JUBILANT INGREVIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 22-07-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 13-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 22-07-2026   11:00:00
End date and time of board meeting 22-07-2026   12:25:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1,25,265.00 1,25,265.00
Other income 1,057.00 1,057.00
Total income 1,26,322.00 1,26,322.00
2 Expenses
(a) Cost of materials consumed 71,370.00 71,370.00
(b) Purchases of stock-in-trade 5,150.00 5,150.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (11,765.00) (11,765.00)
(d) Employee benefit expense 9,760.00 9,760.00
(e) Finance costs 1,430.00 1,430.00
(f) Depreciation, depletion and amortisation expense 4,052.00 4,052.00
(f) Other Expenses
1 Power and fuel expense 13,618.00 13,618.00
2 Others 15,746.00 15,746.00
Total other expenses 29,364.00 29,364.00
Total expenses 1,09,361.00 1,09,361.00
3 Total profit before exceptional items and tax 16,961.00 16,961.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 16,961.00 16,961.00
6 Tax expense
7 Current tax 3,959.00 3,959.00
8 Deferred tax 380.00 380.00
9 Total tax expenses 4,339.00 4,339.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 12,622.00 12,622.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 12,622.00 12,622.00
17 Other comprehensive income net of taxes 4.00 4.00
18 Total Comprehensive Income for the period 12,626.00 12,626.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,593.00 1,593.00
Face value of equity share capital 1593 1593
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.92 7.92
Diluted earnings (loss) per share from continuing operations 7.92 7.92
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.92 7.92
Diluted earnings (loss) per share from continuing and discontinued operations 7.92 7.92
24 Debt equity ratio 0.2300 0.2300
25 Debt service coverage ratio 5.8300 5.8300
26 Interest service coverage ratio 15.6900 15.6900
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Speciality Chemicals 56,853.00 56,853.00
2 Nutrition & Health Solutions 22,457.00 22,457.00
3 Chemical Intermediates 56,527.00 56,527.00
Total Segment Revenue 1,35,837.00 1,35,837.00
Less: Inter segment revenue 10,572.00 10,572.00
Revenue from operations 1,25,265.00 1,25,265.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Speciality Chemicals 10,169.00 10,169.00
2 Nutrition & Health Solutions 1,965.00 1,965.00
3 Chemical Intermediates 8,452.00 8,452.00
Total Profit before tax 20,586.00 20,586.00
i. Finance cost 1,430.00 1,430.00
ii. Other Unallocable Expenditure net off Unallocable income 2,195.00 2,195.00
Profit before tax 16,961.00 16,961.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Speciality Chemicals 2,49,260.00 2,49,260.00
2 Nutrition & Health Solutions 71,523.00 71,523.00
3 Chemical Intermediates 1,40,850.00 1,40,850.00
Total Segment Asset 4,61,633.00 4,61,633.00
Un-allocable Assets 55,111.00 55,111.00
Net Segment Asset 5,16,744.00 5,16,744.00
4 Segment Liabilities
Segment Liabilities
1 Speciality Chemicals 52,471.00 52,471.00
2 Nutrition & Health Solutions 15,656.00 15,656.00
3 Chemical Intermediates 59,931.00 59,931.00
Total Segment Liabilities 1,28,058.00 1,28,058.00
Un-allocable Liabilities 1,11,619.00 1,11,619.00
Net Segment Liabilities 2,39,677.00 2,39,677.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 a) Items that will not be reclassified to profit or loss 5.00 5.00
Total Amount of items that will not be reclassified to profit and loss 5.00
2 Income tax relating to items that will not be reclassified to profit or loss 1.00 1.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 4.00 4.00